Physician profile
Puja Singh
NPI 1841721172
$2,122.00
in general payments reported to CMS, 2019-2025
18 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.71 · 2023: $193 · 2024: $961 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091 · Travel and Lodging: $16.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.09 |
| Travel and Lodging | $16.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.79 | 2023-2025 | Sogroya, Wegovy |
| Dexcom, INC. | $289.79 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $285.15 | 2023-2025 | |
| Tolmar, INC. | $229.22 | 2023-2025 | Fensolvi |
| Azurity Pharmaceuticals, INC. | $214.05 | 2023-2025 | Triptodur, Triptodur |
| Insulet Corporation | $121.56 | 2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $114.81 | 2024-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $112.55 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $75.49 | 2024-2025 | Alkindi, Khindivi, Increlex |
| Neurocrine Biosciences, INC. | $64.77 | 2025 | |
| Pfizer INC. | $57.99 | 2025 | |
| Tandem Diabetes Care, INC. | $51.94 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $49.26 | 2025 | |
| Medtronic, INC. | $39.96 | 2025 | Minimed 780g |
| Sequel Med Tech, LLC | $23.01 | 2025 | Twiist |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.34 | 2025 | Mounjaro |
| Zealand Pharma US, INC. | $14.71 | 2021 | |
| Soleno Therapeutics, INC. | $14.61 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.